Blue Stream Fiber Expands Presence in Cape Coral
'Our services are a vital part of residents' everyday lives, which is why we prioritize building lasting partnerships with HOAs to deliver real solutions,' said Gavin Keirans, President of Blue Stream Fiber. 'Sandoval is an ideal partner because they share our commitment to providing residents with a top-tier fiber network, a true whole-home WiFi service, and exceptional customer support from a local team that truly cares.'
Sandoval, a premier 1,425-home master-planned and gated community in Cape Coral, Florida, spans approximately 524 acres of beautifully maintained grounds, scenic lakes, and nature preserves. Sandoval offers a Caribbean-inspired lifestyle with diverse housing options, including condos, villas, and single-family homes. Frustrated by frequent long-term outages due to a lack of network redundancy, and inadequate customer support from their previous provider, the community sought a reliable alternative. The board assembled a highly skilled committee, engaged a professional consultant in Joe Guertin of YFi Advisors, Inc., and ultimately selected Blue Stream Fiber as their new provider. With Fiber-to-the-Home (FTTH) technology being deployed not only to residences for an improved in-home experience but also to many of the community's common areas, residents and guests will enjoy seamless connectivity for streaming, gaming, and remote work—without lag or buffering.
'Sandoval HOA is thrilled to introduce Blue Stream Fiber to our community, delivering the dependable, high-speed technology that our homeowners have long awaited,' announced Bill Ciminelli, President of the Sandoval HOA Board. 'Following a thorough assessment of various providers with the professional help of YFi Advisors, Blue Stream Fiber distinguished itself with its cutting-edge fiber optic technology and unparalleled customer service, provided by a dedicated local team. This partnership underscores our commitment to fostering enduring relationships and connectivity for the benefit of our residents, both now and in the years to come.'
In addition to providing top-quality telecom services, Blue Stream Fiber's partnership with Sandoval is also expected to increase property values within the community. According to recent studies, communities with access to fiber-optic technology can see a significant increase in their property values.
Blue Stream Fiber has already initiated the fiber construction process to prepare for the activation of its services throughout the community in April 2026.
For more information about Blue Stream Fiber's Bulk offerings, visit www.BlueStreamFiber.com/Bulk.
About Blue Stream Fiber
Blue Stream Fiber provides all customers, including residents, HOAs, COAs, developers, and businesses with the most advanced broadband, television, and voice products all over 100% gigabit-capable networks. With a 45+ year history of providing customers with local and high-touch customer service and world-class future-proof technology, Blue Stream Fiber has become a trusted telecommunications partner throughout Florida and Houston.
About YFi Advisors
YFi Advisors is an independent consulting firm dedicated to driving technology advancement and customer satisfaction within the telecommunications industry. Specializing in negotiation of large-scale bulk telecommunications and easement agreements, YFi Advisors provides expert broadband guidance to residential community associations, property management companies, and real estate developers. With a deep understanding of technology and telecommunications procurement, the firm empowers clients to navigate complex negotiations with confidence and efficiency.
SOURCE: Blue Stream Fiber
Copyright Business Wire 2025.
PUB: 03/26/2025 10:05 AM/DISC: 03/26/2025 10:06 AM
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
a few seconds ago
- Business Wire
PROS Recognized as a Gold Stevie ® Award Winner in the 2025 International Business Awards ®
HOUSTON--(BUSINESS WIRE)-- PROS Holdings, Inc. (NYSE: PRO), a leading provider of AI-powered SaaS pricing and selling solutions, today announced that it was named a winner of a Gold Stevie ® Award in the Business or Competitive Intelligence Solution category in the 22 nd annual International Business Awards ®. 'In a market that shifts by the minute, our AI Agents and the PROS Platform are helping businesses turn complexity into clarity, transforming how they price, sell and serve their customers,' said Jeff Cotten, President and CEO, PROS. This recognition highlighted PROS AI Agents as strong enhancements to the PROS Platform, deeply contextualized to align with each customer's business goals and industry-specific needs. By leveraging advanced natural language processing with PROS prescriptive AI, these intelligent agents interpret and act on data in real time. They operate as intelligent coworkers, streamlining workflows and reducing manual effort across key commercial processes such as pricing, quoting and revenue optimization. 'In a market that shifts by the minute, our AI Agents and the PROS Platform are helping businesses turn complexity into clarity, transforming how they price, sell and serve their customers,' said Jeff Cotten, President and CEO, PROS. 'This win reflects the relentless commitment of our team to deliver AI-powered solutions that enable our customers to make faster, smarter decisions in the moments that matter most.' Judges praised PROS AI Agents for offering a strong approach to AI-powered decision-making and noted the platform's focus on contextual intelligence, automation and actionable insights, which set it apart in a competitive space. One judge added that the PROS Platform 'presents a highly compelling case for innovation in competitive intelligence and pricing optimization,' highlighting its integration of agentic AI for real-time commercial decision-making and its enterprise readiness. The International Business Awards are the world's premier business awards program. All individuals and organizations worldwide – public and private, for-profit and non-profit, large and small – are eligible to submit nominations. The 2025 IBAs received nominations from organizations and individuals in 78 nations and territories. Winners will be celebrated during a gala banquet at the Corinthia Hotel in Lisbon, Portugal on Friday, 10 October. For more information about PROS and its award-winning AI solutions, visit About PROS PROS Holdings, Inc. (NYSE: PRO) is a leading provider of SaaS solutions that optimize omnichannel shopping and selling experiences, powering intelligent commerce. Leveraging leadership in revenue and pricing science, the PROS Platform combines predictive AI, real-time analytics and powerful automation to dynamically match offers to buyers and prices to products. Businesses win more with PROS. Learn how at About the Stevie Awards Stevie Awards are conferred in nine programs: the Asia-Pacific Stevie Awards, the German Stevie Awards, the Middle East & North Africa Stevie Awards, The American Business Awards ®, The International Business Awards ®, the Stevie Awards for Women in Business, the Stevie Awards for Great Employers, the Stevie Awards for Sales & Customer Service, and the Stevie Awards for Technology Excellence. Stevie Awards competitions receive more than 12,000 nominations each year from organizations in more than 70 nations. Honoring organizations of all types and sizes and the people behind them, the Stevies recognize outstanding performances in the workplace worldwide. Learn more about the Stevie Awards at
Business Wire
an hour ago
- Business Wire
Guess?, Inc. to Release Second Quarter Fiscal 2026 Financial Results
LOS ANGELES--(BUSINESS WIRE)--Guess?, Inc. (NYSE: GES) will release its financial results for the second quarter of fiscal year 2026, which ended August 2, 2025, on Wednesday, August 27, 2025. The financial results will be accessible at via the 'Investor Relations' link. In light of the pending take-private transaction announced separately today, Guess? will not host a conference call in connection with its quarterly results. Guess?, Inc. designs, markets, distributes and licenses a lifestyle collection of contemporary apparel, denim, handbags, watches, eyewear, footwear and other related consumer products. Guess? products are distributed through branded Guess? stores as well as better department and specialty stores around the world. At May 3, 2025, the Company directly operated 1,074 retail stores in Europe, the Americas and Asia. The Company's partners and distributors operated 527 additional retail stores worldwide. At May 3, 2025, the Company and its partners and distributors operated in approximately 100 countries worldwide. For more information about the Company, please visit
Business Wire
an hour ago
- Business Wire
RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 27 th Annual Global Investment Conference in New York City, September 8-10, 2025
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- RenovoRx, Inc. ('RenovoRx' or the 'Company') (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath ®, a patented, FDA-cleared drug-delivery device, today announced that Shaun Bagai, Chief Executive Officer, will present at the H.C. Wainwright 27 th Annual Global Investment Conference. The conference will be held at the Lotte New York Palace Hotel in New York City, September 8-10, 2025. Mr. Bagai will be conducting a virtual presentation, which will be available for the duration of the conference, and afterwards on the Company's IR website at Mr. Bagai will discuss RenovoRx's ongoing commercialization efforts and the organic revenue growth reflecting the strong clinical need and market demand for RenovoCath as a standalone targeted drug-delivery product among both new and existing customers. Mr. Bagai's presentation will also highlight the latest developments in RenovoRx's ongoing Phase III TIGeR-PaC clinical trial, including the Data Monitoring Committee's (DMC) recent recommendation to continue the trial following its review of the second pre-planned interim analysis which was triggered by the 52 nd death. The TIGeR-PaC trial is evaluating RenovoRx's novel drug-device combination oncology product candidate (intra-arterial gemcitabine delivered via RenovoCath, known as IAG) for the treatment of locally advanced pancreatic cancer (LAPC). Presentation Details: To schedule a one-on-one investor meeting with Mr. Bagai, please contact KCSA Strategic Communications at RenovoRx@ About RenovoCath Based on its FDA clearance, RenovoCath ® is intended for the isolation of blood flow and delivery of fluids, including diagnostic and/or therapeutic agents, to selected sites in the peripheral vascular system. RenovoCath is also indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. For further information regarding our RenovoCath Instructions for Use ('IFU'), please see: About RenovoRx, Inc. RenovoRx, Inc. (Nasdaq: RNXT) is a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath ®, a novel, U.S. Food and Drug Administration (FDA)-cleared local drug-delivery device, targeting high unmet medical needs. RenovoRx's patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy. RenovoRx's novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and its mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. In addition to the RenovoCath device, RenovoRx is also evaluating its novel drug-device combination oncology product candidate (intra-arterial gemcitabine delivered via RenovoCath, known as IAG) in the ongoing Phase III TIGeR-PaC trial. IAG is being evaluated by the Center for Drug Evaluation and Research (the drug division of the FDA) under a U.S. investigational new drug application that is regulated by the FDA's 21 CFR 312 pathway. IAG utilizes RenovoCath, the Company's patented, FDA-cleared drug-delivery device, indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. The combination product candidate, which is enabled by the RenovoCath device, is currently under investigation and has not been approved for commercial sale. RenovoCath with gemcitabine received Orphan Drug Designation for pancreatic cancer and bile duct cancer, which provides seven years of market exclusivity upon new drug application approval by the FDA. RenovoRx is also actively commercializing its TAMP technology and FDA-cleared RenovoCath as a stand-alone device. In December 2024, RenovoRx announced the receipt of its first commercial purchase orders for RenovoCath devices. Additionally, several of these customers have already initiated repeat orders in parallel to RenovoRx expanding the number of medical institutions initiating new RenovoCath orders, including several esteemed, high-volume National Cancer Institute-designated centers. To meet and satisfy the anticipated demand, RenovoRx will continue to actively explore further revenue-generating activity, either on its own or in tandem with a medical device commercial partner. For more information, visit Follow RenovoRx on Facebook, LinkedIn, and X. Cautionary Note Regarding Forward-Looking Statements This press release and statements of the Company's management made in connection therewith and at the investor conference described herein contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding (i) our clinical trials and studies, including anticipated timing, statements regarding the potential of RenovoCath ® or TAMP™ or regarding our ongoing TIGeR-PaC Phase III clinical trial study in LAPC, (ii) the potential for our product candidates to treat or provide clinically meaningful outcomes for certain medical conditions or diseases and (iii) our efforts to explore commercialization strategies utilizing our TAMP technology. Statements that are not purely historical are forward-looking statements. The forward-looking statements contained herein are based upon our current expectations and beliefs regarding future events, many of which, by their nature, are inherently uncertain, outside of our control and involve assumptions that may never materialize or may prove to be incorrect. These may include estimates, projections and statements relating to our research and development plans, intellectual property development, clinical trials, our therapy platform, business plans, financing plans, objectives and expected operating results, which are based on current expectations and assumptions that are subject to known and unknown risks and uncertainties that may cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These statements may be identified using words such as 'may,' 'expects,' 'plans,' 'aims,' 'anticipates,' 'believes,' 'forecasts,' 'estimates,' 'intends,' and 'potential,' or the negative of these terms or other comparable terminology regarding RenovoRx's expectations strategy, plans or intentions, although not all forward-looking statements contain these words. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, that could cause actual events to differ materially from those projected or indicated by such statements, including, among other things: (i) the risk that our exploration of commercial opportunities for our TAMP technology may not lead to viable, revenue generating operations; (ii) circumstances which would adversely impact our ability to efficiently utilize our cash resources on hand or raise additional funding, (iii) the timing of the initiation, progress and potential results (including the results of interim analyses) of our preclinical studies, clinical trials and our research programs; (iv) the possibility that interim results may not be predictive of the outcome of our clinical trials, which may not demonstrate sufficient safety and efficacy to support regulatory approval of our product candidate, (v) that the applicable regulatory authorities may disagree with our interpretation of the data; research and clinical development plans and timelines, and the regulatory process for our product candidates; (vi) future potential regulatory milestones for our product candidates, including those related to current and planned clinical studies; (vii) our ability to use and expand our therapy platform to build a pipeline of product candidates; (viii) our ability to advance product candidates into, and successfully complete, clinical trials; (ix) the timing or likelihood of regulatory filings and approvals; (x) our estimates of the number of patients who suffer from the diseases we are targeting and the number of patients that may enroll in our clinical trials; (xi) the commercialization potential of our product candidates, if approved; (xii) our ability and the potential to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if approved; (xiii) future strategic arrangements and/or collaborations and the potential benefits of such arrangements; (xiv) our estimates regarding expenses, future revenue, capital requirements and needs for additional financing and our ability to obtain additional capital; (xv) the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements; (xvi) our ability to retain the continued service of our key personnel and to identify, and hire and retain additional qualified personnel; (xvii) the implementation of our strategic plans for our business and product candidates; (xviii) the scope of protection we are able to establish and maintain for intellectual property rights, including our therapy platform, product candidates and research programs; (xix) our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; (xx) the pricing, coverage and reimbursement of our product candidates, if approved; and (xxi) developments relating to our competitors and our industry, including competing product candidates and therapies. Information regarding the foregoing and additional risks may be found in the section entitled 'Risk Factors' in documents that we file from time to time with the Securities and Exchange Commission. Forward-looking statements included herein are made as of the date hereof, and RenovoRx does not undertake any obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as required by law.
